Prior to joining Amicus, Mr. Doshi founded RStreet Advisors, a healthcare consulting firm through which he advised pharmaceutical, biotech and diagnostics companies on business development, corporate strategy, market and commercial planning activities. From 2008 to 2013, Mr. Doshi was the Senior Vice President and member of the management team at Auven Therapeutics, a 200MM+ global private equity and bio-pharmaceutical development company. Mr. Doshi led or participated in the operations and financing of several biotech and pharmaceutical companies and held Board Observer positions for both Spirogen (acquired by AstraZeneca) and ADC Therapeutics.
From 2005 to 2008, Mr. Doshi was the Head of Corporate Development for Catalent Pharma Solutions (CTLT). Prior to Catalent, Mr. Doshi was a member of Merrill Lynch's Investment Banking Group. During his tenure at Eli Lilly, Mr. Doshi was a member of both the Strategic Marketing team and Lilly Ventures where he developed and led a portfolio company. He was also a sales representative in New York. As a consultant for both Mercer Management Consulting (Oliver Wyman) and Sapient Corporation (Publicis), Mr. Doshi advised healthcare, consumer and technology companies.
Mr. Doshi received a B.A. from Rutgers University and an M.B.A. from The Wharton School of the University of Pennsylvania.